274 related articles for article (PubMed ID: 10335865)
41. Vpr is required for efficient Nef expression from unintegrated human immunodeficiency virus type 1 DNA.
Poon B; Chang MA; Chen IS
J Virol; 2007 Oct; 81(19):10515-23. PubMed ID: 17652391
[TBL] [Abstract][Full Text] [Related]
42. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
[TBL] [Abstract][Full Text] [Related]
43. Interaction of pregnancy steroid hormones and zidovudine in inhibition of HIV type 1 replication in monocytoid and placental Hofbauer cells: implications for the prevention of maternal-fetal transmission of HIV.
Lee AW; Mitra D; Laurence J
AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1235-42. PubMed ID: 9310291
[TBL] [Abstract][Full Text] [Related]
44. Derivation of a biologically contained replication system for human immunodeficiency virus type 1.
Chen H; Boyle TJ; Malim MH; Cullen BR; Lyerly HK
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7678-82. PubMed ID: 1502183
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro.
Montaner LJ; Griffin P; Gordon S
J Gen Virol; 1994 Dec; 75 ( Pt 12)():3393-400. PubMed ID: 7527834
[TBL] [Abstract][Full Text] [Related]
46. Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.
Robinson LH; Gale CV; Kleim JP
J Virol Methods; 2002 Jul; 104(2):147-60. PubMed ID: 12088824
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the presence of 2-LTR HIV-1 unintegrated DNA as a simple molecular predictor of disease progression.
Zazzi M; Romano L; Catucci M; Venturi G; De Milito A; Almi P; Gonnelli A; Rubino M; Occhini U; Valensin PE
J Med Virol; 1997 May; 52(1):20-5. PubMed ID: 9131453
[TBL] [Abstract][Full Text] [Related]
48. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.
Vitone F; Gibellini D; Schiavone P; Re MC
J Clin Virol; 2005 Jul; 33(3):194-200. PubMed ID: 15911440
[TBL] [Abstract][Full Text] [Related]
49. Activating protein-1 cooperates with phorbol ester activation signals to increase HIV-1 expression.
Roebuck KA; Gu DS; Kagnoff MF
AIDS; 1996 Jul; 10(8):819-26. PubMed ID: 8828738
[TBL] [Abstract][Full Text] [Related]
50. HIV-1 proteinase is required for synthesis of pro-viral DNA.
Baboonian C; Dalgleish A; Bountiff L; Gross J; Oroszlan S; Rickett G; Smith-Burchnell C; Troke P; Merson J
Biochem Biophys Res Commun; 1991 Aug; 179(1):17-24. PubMed ID: 1652947
[TBL] [Abstract][Full Text] [Related]
51. Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7.
Beq S; Bugault F; Colle JH; Lambotte O; Delfraissy JF; Thèze J
Eur Cytokine Netw; 2005 Dec; 16(4):293-9. PubMed ID: 16464744
[TBL] [Abstract][Full Text] [Related]
52. HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
Uchida H; Maeda Y; Mitsuya H
Antiviral Res; 1997 Nov; 36(2):107-13. PubMed ID: 9443667
[TBL] [Abstract][Full Text] [Related]
53. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
[TBL] [Abstract][Full Text] [Related]
54. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A.
Johnson VA; Barlow MA; Merrill DP; Chou TC; Hirsch MS
J Infect Dis; 1990 Jun; 161(6):1059-67. PubMed ID: 2345291
[TBL] [Abstract][Full Text] [Related]
55. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.
Wu Y; Marsh JW
Science; 2001 Aug; 293(5534):1503-6. PubMed ID: 11520990
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.
Bilello JA; Bilello PA; Kort JJ; Dudley MN; Leonard J; Drusano GL
Antimicrob Agents Chemother; 1995 Nov; 39(11):2523-7. PubMed ID: 8585738
[TBL] [Abstract][Full Text] [Related]
58. A sensitive and versatile bioluminescence bioassay for HIV type 1 based on adenoviral vectors.
Axelrod JH; Honigman A
AIDS Res Hum Retroviruses; 1999 May; 15(8):759-67. PubMed ID: 10357471
[TBL] [Abstract][Full Text] [Related]
59. Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sullivan AK; Burton CT; Nelson MR; Moyle G; Mandalia S; Gotch FM; Gazzard BG; Imami N
Scand J Immunol; 2003 Jun; 57(6):600-7. PubMed ID: 12791099
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs.
Kashanchi F; Sadaie MR; Brady JN
Virology; 1997 Jan; 227(2):431-8. PubMed ID: 9018142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
